Global investment firm KKR’s India healthcare portfolio is expanding further with KKR-backed Baby Memorial Hospital set to acquire a 60% stake in Hyderabad-based Star Hospitals for Rs 1,800 crore — a transaction that values the Star Hospitals chain at Rs 3,000 crore and represents one of the most significant healthcare consolidation deals in southern India in recent memory.
The deal brings together two established hospital networks under KKR’s broader Indian healthcare strategy — Baby Memorial Hospital, a prominent tertiary care institution in Kozhikode, Kerala, and Star Hospitals, a multi-specialty hospital group with a significant presence in Hyderabad’s competitive and rapidly growing private healthcare market. The combination creates a southern India-focused hospital platform with geographic reach across both Kerala and Telangana — two states with strong healthcare demand dynamics driven by medical tourism, rising health insurance penetration, and growing middle-class expenditure on private healthcare.
The valuation and structure
At Rs 3,000 crore for 100% of Star Hospitals, the deal implies a valuation that reflects both the chain’s current revenue and EBITDA profile and the premium that KKR and its portfolio company are willing to pay for a controlling stake in a quality Hyderabad hospital asset. The 60% stake acquisition for Rs 1,800 crore leaves the remaining 40% with existing shareholders — likely the founding promoters — creating a structure where operational continuity and local management expertise are retained while KKR’s capital and strategic network drive expansion and professionalisation.
For Baby Memorial Hospital, the acquisition is a geographic diversification that takes it out of Kerala for the first time at scale. Hyderabad is one of India’s fastest-growing private healthcare markets, driven by the city’s large IT and pharmaceutical sector workforce, its growing insurance coverage, and its emergence as a medical tourism destination for patients from neighbouring states and from Southeast Asian countries. Gaining a controlling position in a Hyderabad hospital chain through Star Hospitals gives the combined platform access to that market without the cost and time of greenfield development.
KKR’s Indian healthcare strategy
The Star Hospitals deal is consistent with KKR’s clearly defined and consistently executed Indian healthcare investment thesis. The firm’s existing Indian healthcare portfolio spans multiple segments — Healthium MedTech in medical devices, HCG in oncology, JB Pharma and Gland Pharma in pharmaceuticals. The addition of a hospital platform through Baby Memorial’s acquisition of Star Hospitals completes KKR’s vertical coverage across the Indian healthcare value chain from pharmaceuticals through devices to hospital services.
KKR has been one of the most active foreign private equity investors in Indian healthcare over the past decade, consistently backing the thesis that India’s healthcare infrastructure is significantly underpenetrated relative to its population size, income growth trajectory, and disease burden — and that professionally managed, capital-backed hospital chains can generate attractive returns by consolidating fragmented regional markets. The Rs 3,000 crore valuation of Star Hospitals at the time of acquisition, compared to the much higher valuations that listed Indian hospital chains command, suggests KKR sees meaningful re-rating potential as the platform scales and potentially prepares for a public market listing.
Star Hospitals’ position in Hyderabad
Star Hospitals is an established multi-specialty hospital group in Hyderabad with facilities offering tertiary and quaternary care across cardiology, oncology, neurosciences, orthopaedics, and other high-acuity specialties. Hyderabad’s private hospital market is competitive — anchored by large chains including Apollo Hospitals, KIMS, Yashoda, and Continental — but demand growth has been sufficiently strong to support multiple players expanding simultaneously. Star Hospitals’ positioning within that competitive landscape and the operational improvements that KKR’s capital and management support can enable will determine the pace at which the Rs 3,000 crore entry valuation grows toward the exit valuation KKR will be targeting.
The India healthcare macro tailwind
The deal arrives at a moment when India’s private healthcare sector is receiving sustained investor attention driven by several structural factors. Health insurance penetration, while still low by developed market standards, has been growing rapidly through government schemes like Ayushman Bharat and expanding corporate and retail insurance. The post-Iran-war economic environment — with elevated inflation, currency pressure, and fiscal constraints limiting government health spending capacity — makes the case for private healthcare investment more rather than less compelling, as the gap between public healthcare supply and population demand continues to widen.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Deal details are sourced from publicly available reporting. Readers are advised to consult a financial advisor before making any investment decisions. Business Upturn is not responsible for any decisions made based on this article.